A carregar...

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Tringale, Kathryn R, Carroll, Kate T, Zakeri, Kaveh, Sacco, Assuntina G, Barnachea, Linda, Murphy, James D
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5946900/
https://ncbi.nlm.nih.gov/pubmed/29126314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!